泰嘉錠在英國的末期乳癌治療健保許可受創，經濟不景象之下，生命的成本要更精算了。

英國NICE(相當於健保機構)，拒絕Tykerb合併Xeloda對於晚期Her2陽性乳癌患者的健保申請，雖然可增加病患的無疾病惡化存活率，但不符成本效益。

Glaxo’s Tykerb rejected by UK agency for breast cancer use- (Bloomberg)

NICE refuses funding for advanced breast cancer treatment, Tyverb (lapatinib) - (GlaxoSmithKline)

Watchdog rejects costly breast cancer drug - (International Herald Tribune)

Breast cancer (advanced or metastatic) - lapatinib: final appraisal determination - (NHS)

NICE also "minded" to reject Pfizer's Sutent for GIST - (The Guardian)